Literature DB >> 10454179

The rate of diagnosis and demography of pelvic inflammatory disease in general practice: England and Wales.

I Simms1, P Rogers, A Charlett.   

Abstract

Knowledge of pelvic inflammatory disease (PID) epidemiology is essential to the understanding of reproductive morbidity in women. This paper estimates the rate of PID diagnosis in general practice (GP) and the level of association between PID diagnosis and demographic factors. Diagnoses of PID were made at 1.7% of attendances amongst women aged 16 to 46. Increased risk of PID was associated with smoking (P<0.0001), younger age groups (P<0.0001) and lower socioeconomic groups (P<0.0001). Compared to patients who were married, increased risk was also associated with those patients who were widowed, separated or divorced and not cohabiting (adjusted rate ratio (RR)=1.62; confidence limits (CL) 1.35 to 1.97), and with those who were unmarried but cohabiting (adjusted RR=1.32; 95% CL 1.11 to 1.56). General practice is an important focus for the diagnosis and treatment of PID. If intervention and surveillance are to be undertaken effectively, more has to be known about the epidemiology of this important public health problem.

Entities:  

Mesh:

Year:  1999        PMID: 10454179     DOI: 10.1258/0956462991914447

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  14 in total

Review 1.  Pelvic inflammatory disease epidemiology: what do we know and what do we need to know?

Authors:  I Simms; J M Stephenson
Journal:  Sex Transm Infect       Date:  2000-04       Impact factor: 3.519

2.  Influence of material deprivation on hospital admissions for gynaecologic infections.

Authors:  B Olowokure; J I Hawker; S Harcourt; F Warburton; J Weinberg; R C Wilson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-06-25       Impact factor: 3.267

3.  Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.

Authors:  J D C Ross; H S Cronjé; T Paszkowski; I Rakoczi; D Vildaite; A Kureishi; M Alefelder; P Arvis; P Reimnitz
Journal:  Sex Transm Infect       Date:  2006-05-24       Impact factor: 3.519

4.  Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: the Uppsala Women's Cohort Study.

Authors:  N Low; M Egger; J A C Sterne; R M Harbord; F Ibrahim; B Lindblom; B Herrmann
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

5.  Management of first-episode pelvic inflammatory disease in primary care: results from a large UK primary care database.

Authors:  Amanda Nicholson; Greta Rait; Tarita Murray-Thomas; Gwenda Hughes; Catherine H Mercer; Jackie Cassell
Journal:  Br J Gen Pract       Date:  2010-10       Impact factor: 5.386

6.  Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial.

Authors:  Pippa Oakeshott; Sally Kerry; Adamma Aghaizu; Helen Atherton; Sima Hay; David Taylor-Robinson; Ian Simms; Phillip Hay
Journal:  BMJ       Date:  2010-04-08

Review 7.  Pelvic inflammatory disease.

Authors:  Jonathan D C Ross
Journal:  BMJ Clin Evid       Date:  2008-03-10

8.  Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS.

Authors:  Paula H Bednarek; Jeffrey T Jensen
Journal:  Int J Womens Health       Date:  2010-08-09

Review 9.  Mycoplasma genitalium: an emerging cause of pelvic inflammatory disease.

Authors:  Catherine L Haggerty; Brandie D Taylor
Journal:  Infect Dis Obstet Gynecol       Date:  2011-12-25

10.  The clinical diagnosis of pelvic inflammatory disease--reuse of electronic medical record data from 189 patients visiting a Swedish university hospital emergency department.

Authors:  Jan Eggert; Kristina Sundquist; Caroline van Vuuren; Aino Fianu-Jonasson
Journal:  BMC Womens Health       Date:  2006-10-21       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.